RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations

International Journal of Hematology

Volumn 94, Issue 3, 2011, Pages 255-260

  Inokuchi, Koiti ^a   Wakita, Satoshi ^a   Hirakawa, Tsuneaki ^a   Tamai, Hayato ^a   Yokose, Norio ^a   Yamaguchi, Hiroki ^a   Dan, Kazuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

B lymphoblastic leukemia; Dexamethasone; RCSD1 ABL1 fusion gene; TKI

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; IMATINIB; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BASOPHIL; BONE MARROW BIOPSY; CHROMOSOMAL INSTABILITY; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHROMOSOME G BAND; CLONE; DRUG SENSITIVITY; EXON; FEMORAL VEIN; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENETIC TRANSCRIPTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; KARYOTYPE; LEG THROMBOSIS; LYMPHOCYTE COUNT; MALE; MONOCYTE; NEUTROPHIL COUNT; PERIODIC ACID SCHIFF STAIN; RCSD1 ABL1 GENE; RECIPROCAL CHROMOSOME TRANSLOCATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SKIN ABSCESS; SPECTRAL KARYOTYPING; THORAX PAIN; THROMBOCYTE COUNT;

ABNORMAL KARYOTYPE; ACUTE DISEASE; ADULT; BASE SEQUENCE; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; EXONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, B-CELL; MALE; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; TRANSLOCATION, GENETIC;

EID: 84860417249     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0910-z     Document Type: Article

References (17)

1. De Klein A, Geurts van Kessel A, Gorsveld G, et al. A cellular oncogene is translocated to Philadelphia chromosome in chronic myelocytic leukemia. Nature. 1982;300:765-7. (Pubitemid 13224358)
2. De Klein A, Hagemeijer A, Bartram CR, Houwen R, et al. bcr rearrangement and translocation of the c-abl oncogene to Philadelphia positive acute lymphoblastic leukemia. Blood. 1986;68: 1369-75. (Pubitemid 17228817)
3. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, et al. Molecular cytogenetic and clinical findings in ETV6/ABL1- positive leukemia. Gene Chromosome Cancer. 2001;30:274-82. (Pubitemid 32126204)
4. Meyer-Monard S, Muhlematter D, Streit A, Chase AJ, et al. Broad molecular screening of an unclassible myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia. 2005;19:1096-9. (Pubitemid 40862029)
5. Graux C, Cools J, Melotte C, Quentmeier H, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36:1084-9. (Pubitemid 41184470)
6. De Keersmaecker K, Graux C, Odero MD, Mentens N, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005;105:4849-52. (Pubitemid 40807313)
7. Mustjoki S, Hernesniemi S, Rauhala A, Kahkonen M, et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica. 2009;94:1469-71.
8. Thomas DA, Faderi S, Cortes J, O'Brien S, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103: 4396-407. (Pubitemid 38745962)
9. Ravandi F, O'Brien S, Thomas D, Faderi S, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph?) acute lymphoblastic leukemia. Blood. 2010;116:2070-7.
10. ISCN 2005. An international system for human cytogenetic nomenclature (2005). In: Shaffer LG, Tommerup N, editors. Basel: Karger publishers; 2005.
11. Abo J, Inokuchi K, Dan K, Nomura T. p53 and N-ras mutations in two new leukemia cell lines established from a patient with multilineage CD-7positive acute leukemia. Blood. 1993;82: 2829-36. (Pubitemid 23318091)
12. Inokuchi K, Shinohara T, Futaki M, Hanawa H, et al. Establishment of a cell line with variant BCR/ABL breakpoint expression P180 BCR/ABL from late-appearing Philadelphiapositive acute biphenotypic leukemia. Gene Chromosome Cancer. 1998;23:227-38. (Pubitemid 28465639)
13. Inokuchi K, Hamaguchi H, Taniwaki M, Yamaguchi H, Tanosaki S. Establishment of cell line with AML1-MTG8, TP53, and TP73 abnormalities form acute myelogenous leukemia. Gene Chromosome Cancer. 2001;32:182-7.
14. Suessmuth Y, Elliott J, Percy MJ, Inami M, et al. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol. 2009 147 450-8.
15. Inami M, Inokuchi K, Nakayama K, Tamura H, et al. Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia. Int J Hematol. 2003;78:173-5. (Pubitemid 37021962)
16. Garcia JRG, Bohlander SK, Angulo MG, Flores MAE, et al. A t(1;9)(q23.3 q25:q34) affecting the ABL1 gene in a biphenotypic leukemia. Cancer Genet Cytogenet. 2004;152:81-3. (Pubitemid 38757384)
17. Braekeller EDE, Douet-Guilbert N, Le Bris MJ, Berthou C, et al. A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Leukemia. 2007;21:2220-1. (Pubitemid 47423823)